Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma

摘要

Lung cancer is the mostcommon type ofcancer worldwide with a highmortality rate. The majority of patientsare diagnosed atan advanced stage becausethetumor is typically asymptomaticforalong time. [1,2] Primary lung cancer includes thefollowing 2 pathologicaltypes: non-small-celllung cancer (NSCLC)and small-celllung cancer (SCLC). NSCLC accounts for the majority ofall newly diagnosed lung cancers, which include many pathologicalsubtypes, such asadenocarcinoma, squamouscarcinoma,and large-cellcarcinoma. [3,4] Chemotherapy and radiotherapywere mainly used to treatadvanced metastaticlung cancer, beforetheadvent oftargeted therapy. After treatment, the mortality rate of patients with lung cancer has notchanged to a greatextent. [2] Epidermal growth factor receptor (EGFR)/ERBB1/HER1, which isa member ofthe EGFRfamily, isa transmembrane proteinwith cytoplasmic kinaseactivity.